Development of a functional outcome measure for riboflavin transporter deficiency

被引:1
|
作者
Fennessy, Jack R. [1 ]
Donlevy, Gabrielle A. [1 ,2 ]
Mckay, Marnee J. [1 ]
Burns, Joshua [1 ,2 ]
Cornett, Kayla M. D. [1 ,2 ]
Menezes, Manoj P. [3 ,4 ,5 ]
机构
[1] Univ Sydney, Fac Med & Hlth, Sch Hlth Sci, Sydney, NSW, Australia
[2] Sydney Childrens Hosp Network, Paediat Gait Anal Serv New South Wales, Westmead, NSW, Australia
[3] Univ Sydney, Westmead Clin Sch, Fac Med & Hlth, Childrens Hosp, Sydney, NSW, Australia
[4] Childrens Hosp Westmead, TY Nelson Dept Neurol & Neurosurg, Sydney, NSW, Australia
[5] Childrens Hosp Westmead, TY Nelson Dept Neurol & Neurosurg, Westmead, NSW 2145, Australia
关键词
clinical outcome assessment; clinical trials; endpoint; performance outcome measure; riboflavin transporter deficiency; MARIE-TOOTH DISEASE; REFERENCE VALUES; MUTATIONS; VARIABILITY; VALIDATION; SCALE;
D O I
10.1111/jns.12619
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and AimsRiboflavin transporter deficiency (RTD) is a progressive inherited neuropathy of childhood onset, characterised clinically by pontobulbar palsy, sensory ataxia, sensorineural deafness, muscle weakness, optic atrophy and respiratory failure. A robust and responsive functional outcome measure is essential for future clinical trials of disease-modifying therapies including genetic therapies. The Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS) is a well-validated outcome measure for CMT and related neuropathies, and might have utility for measuring disease progression in individuals with RTD. However, the CMTPedS requires modifications to account for phenotypic differences between children with CMT and RTD. The aim of this study was to develop a functional outcome measure based on the CMTPedS for specific use in individuals with RTD.MethodsThe CMTPedS data collected over the last 10 years in individuals with RTD attending the Peripheral Neuropathy Management Clinic at the Children's Hospital at Westmead (Sydney, Australia) were reviewed to evaluate each item within the CMTPedS. A literature review of articles published until September 2021 for functional outcome measures generated an item pool for pilot testing. The results of this pilot testing, alongside analysis of existing CMTPedS item scores in the RTD cohort, informed the modification of the CMTPedS.ResultsCMTPedS data were reviewed for eight individuals over the past 10 years. Two items were identified as requiring modification or removal and additional items of proximal strength and function needed to be considered. Six studies were identified in the literature review, and five items were selected for pilot testing. 'Shoulder internal rotation' and the '30-s sit to stand test' were added as proximal measures of strength and function. The composite balance item comprising nine tasks in the CMTPedS showed a ceiling effect and was replaced with the single 'Feet apart on a line eyes open' balance item. 'Pinprick sensation' was removed due to a floor effect.InterpretationThis study provides preliminary evidence that the Riboflavin Transporter Deficiency Pediatric Scale (RTDPedS) is a functional outcome measure covering strength, upper and lower limb function, balance and mobility for individuals with RTD to assess disease severity and progression in clinical trials and cohort studies.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 50 条
  • [1] DEVELOPMENT OF A FUNCTIONAL OUTCOME MEASURE FOR PATIENTS WITH RIBOFLAVIN TRANSPORTER DEFICIENCY
    Fennessy, Jack
    Donlevy, Gabrielle
    Mckay, Marnee
    Burns, Joshua
    Menezes, Manoj
    Cornett, Kayla
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S13 - S14
  • [2] Development of a riboflavin-responsive model of riboflavin transporter deficiency in zebrafish
    Choueiri, Catherine M.
    Lau, Jarred
    O'Connor, Emily
    Dibattista, Alicia
    Wong, Brittany Y.
    Spendiff, Sally
    Horvath, Rita
    Pena, Izabella
    Mackenzie, Alexander
    Lochmuller, Hanns
    HUMAN MOLECULAR GENETICS, 2024, 34 (03) : 265 - 276
  • [3] Riboflavin transporter deficiency
    Serdaroglu, E.
    Konuskan, B.
    Haliloglu, G.
    Alikasifoglu, M.
    Topaloglu, H.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S206 - S206
  • [4] Use of the CMTPedS as a clinical outcome assessment for children with riboflavin transporter deficiency
    Cornett, Kayla
    Burns, Joshua
    Bray, Paula
    Donlevy, Gabrielle
    Menezes, Manoj
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 546 - 547
  • [5] Functional status in limb deficiency: Development of an outcome measure for preschool children
    Pruitt, SD
    Varni, JW
    Seid, M
    Setoguchi, Y
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 1998, 79 (04): : 405 - 411
  • [6] Functional status in children with limb deficiency: Development and initial validation of an outcome measure
    Pruitt, SD
    Varni, JW
    Setoguchi, Y
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 1996, 77 (12): : 1233 - 1238
  • [7] Ocular Biomarkers of Riboflavin Transporter Deficiency
    Bulas, Sabrina
    Bedoukian, Emma C.
    O'Neil, Erin C.
    Krantz, Ian D.
    Yum, Sabrina W.
    Liu, Grant T.
    Aleman, Tomas S.
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2023, 43 (01) : 110 - 115
  • [8] A riboflavin excretion test as a measure of riboflavin deficiency in man
    Najjar, VA
    Holt, LE
    BULLETIN OF THE JOHNS HOPKINS HOSPITAL, 1941, 69 (05): : 476 - 481
  • [9] Impact of natural mutations on the riboflavin transporter 2 and their relevance to human riboflavin transporter deficiency 2
    Console, Lara
    Tolomeo, Maria
    Cosco, Jessica
    Massey, Keith
    Barile, Maria
    Indiveri, Cesare
    IUBMB LIFE, 2022, 74 (07) : 618 - 628
  • [10] Riboflavin transporter deficiency unmasked by dietary changes
    Bosch, Annet
    Jaeger, Bregje
    Langeveld, Mirjam
    Brunkhorst, Robert
    Disterlmaier, Felix
    Wolf, Nicole
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (04)